Key result
Myosin light chain 3 (MYL3) acts as a novel receptor for nervous necrosis virus, facilitating viral entry into host cells via the macropinocytosis pathway through the IGF1R-Rac1/Cdc42 axis.
Why the study?
Host factors involved in nervous necrosis virus entry remain poorly understood despite the virus posing significant threats to fish populations.
Myosin light chain 3 (MmMYL3) acts as a novel receptor for nervous necrosis virus entry via macropinocytosis, presenting a potential antiviral target for fish populations.
Nodaviridae infections cause severe mortality in insects and fish, with nervous necrosis virus (NNV) posing significant threats to global fish populations. However, the host factors involved in NNV entry remain poorly understood. We identify myosin light chain 3 from marine medaka (Oryzias melastigma) (MmMYL3) as a novel receptor for red-spotted grouper NNV (RGNNV), facilitating internalization via macropinocytosis. MmMYL3 directly binds the RGNNV capsid protein (CP), which dependents on the arm and S domains of CP and the EF-hand2 domain of MmMYL3. In vitro experiments showed that MmMYL3 siRNA, protein, anti-MYL3 antibodies or the arm domain synthetic peptides blocked RGNNV entry. Moreover, in vivo administration of MmMYL3 protein also inhibited RGNNV infection. Ectopic MmMYL3 expression enabled RGNNV internalization into resistant cells. Notably, MmMYL3 facilitated RGNNV internalization through the macropinocytosis pathway via the IGF1R-Rac1/Cdc42 axis. Collectively, our findings underscore MYL3’s crucial role in NNV entry and its potential as an antiviral target.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2025) studied Nervous necrosis virus (NNV) infection. MmMYL3 modulation (recombinant protein, siRNA, antibodies) vs. Control (GST protein, mock transfection, etc.) was evaluated on Viral entry and survival rate. Myosin light chain 3 (MYL3) acts as a novel receptor for nervous necrosis virus, facilitating viral entry into host cells via the macropinocytosis pathway through the IGF1R-Rac1/Cdc42 axis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: